ResMed (NYSE:RMD) reported third-quarter fiscal 2026 results highlighted by revenue growth, gross margin expansion, and higher non-GAAP earnings per share, while also announcing a CFO transition and a ...
Q3 reiterated FY 2026 gross margin range “62% to 63%” (CFO Sandercock), consistent with Q2’s updated FY 2026 gross margin range.
12d
ResMed Inc (RMD) Q3 2026 Earnings Call Highlights: Strong Revenue Growth and Strategic Acquisitions
ResMed Inc (RMD) reports an 11% revenue increase and strategic acquisition plans, while navigating supply chain challenges and competitive pressures.
This healthcare business has exposure to a large underdiagnosed market, strong recent momentum, and a growing digital ...
The ASX healthcare share's price has softened recently, but the long-term investment case remains firmly intact for patient ...
Resmed Inc () has held its Q3 earnings call. Read on for the main highlights of the call. Claim 55% Off TipRanks. Unlock hedge fund-level data and powerful investing tools for sma ...
Take advantage of our free shipping offer for this item! We offer free shipping on all parcel shipments within the contiguous United States. For further information, please refer to our Shipping ...
What is the current share price of ResMed Inc. (RMD)? ResMed Inc.'s (RMD) current share price is $28.21. This constitutes a price movement of 4.60% when compared to the share price 7 days ago and is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results